US OptionsDetailed Quotes
HOOK240816C7500
- 0.40
- +0.30+300.00%
15min DelayClose Jul 23 15:57 ET
0.40High0.25Low
0.25Open0.10Pre Close10 Volume10 Open Interest7.50Strike Price340.00Turnover125.84%IV26.40%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.3480Delta0.1827Gamma15.63Leverage Ratio-0.0159Theta0.0012Rho5.44Eff Leverage0.0059Vega
HOOKIPA Pharma Stock Discussion
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - July 10,2024
Ladies and gentleman, On the 17 June 2024, 5 directors and 1 chairperson have collectively bought over 340K of shares at around 0.71 $.
Just wanted to share .... 😊
Up down up down, these shorties will never let us live in peace 🤬🤬🤬
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...
No comment yet